company background image
TSTL

Tristel AIM:TSTL Stock Report

Last Price

UK£3.40

Market Cap

UK£160.6m

7D

0%

1Y

-41.4%

Updated

25 May, 2022

Data

Company Financials +
TSTL fundamental analysis
Snowflake Score
Valuation2/6
Future Growth4/6
Past Performance1/6
Financial Health6/6
Dividends3/6

TSTL Stock Overview

Tristel plc develops, manufactures, and sells infection prevention products in the United Kingdom and internationally.

Tristel Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Tristel
Historical stock prices
Current Share PriceUK£3.40
52 Week HighUK£6.70
52 Week LowUK£2.70
Beta0.61
1 Month Change6.25%
3 Month Change6.25%
1 Year Change-41.38%
3 Year Change10.57%
5 Year Change62.29%
Change since IPO580.00%

Recent News & Updates

Feb 24
Bearish: Analysts Just Cut Their Tristel plc (LON:TSTL) Revenue and EPS estimates

Bearish: Analysts Just Cut Their Tristel plc (LON:TSTL) Revenue and EPS estimates

Today is shaping up negative for Tristel plc ( LON:TSTL ) shareholders, with the analysts delivering a substantial...

Shareholder Returns

TSTLGB Medical EquipmentGB Market
7D0%-0.6%-0.4%
1Y-41.4%-16.9%-3.0%

Return vs Industry: TSTL underperformed the UK Medical Equipment industry which returned -16.9% over the past year.

Return vs Market: TSTL underperformed the UK Market which returned -3% over the past year.

Price Volatility

Is TSTL's price volatile compared to industry and market?
TSTL volatility
TSTL Average Weekly Movement6.6%
Medical Equipment Industry Average Movement6.2%
Market Average Movement6.0%
10% most volatile stocks in GB Market11.6%
10% least volatile stocks in GB Market3.1%

Stable Share Price: TSTL is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: TSTL's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1993196Paul Swinneyhttps://www.tristel.com

Tristel plc develops, manufactures, and sells infection prevention products in the United Kingdom and internationally. The company operates through three segments: Hospital Medical Device Decontamination, Hospital Environmental Surface Disinfection, and Other. It offers medical instrument disinfection products, including airway management, cardiology, ear, nose and throat, endoscopy, ophthalmology, phlebotomy, reproductive health/IVF, surface, ultrasound, urology, women's health, and other products under the Tristel brand; contamination control products, which include cleanroom, laboratory, pharmaceutical, cosmetic, and toiletry disinfectants under the Crystel brand; and airborne and veterinary device disinfectants under the Anistel brand.

Tristel Fundamentals Summary

How do Tristel's earnings and revenue compare to its market cap?
TSTL fundamental statistics
Market CapUK£160.56m
Earnings (TTM)UK£2.29m
Revenue (TTM)UK£29.92m

70.2x

P/E Ratio

5.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
TSTL income statement (TTM)
RevenueUK£29.92m
Cost of RevenueUK£6.14m
Gross ProfitUK£23.78m
Other ExpensesUK£21.50m
EarningsUK£2.29m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.048
Gross Margin79.49%
Net Profit Margin7.64%
Debt/Equity Ratio0%

How did TSTL perform over the long term?

See historical performance and comparison

Dividends

1.9%

Current Dividend Yield

135%

Payout Ratio

Valuation

Is Tristel undervalued compared to its fair value and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


28.6%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: TSTL (£3.4) is trading below our estimate of fair value (£4.76)

Significantly Below Fair Value: TSTL is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: TSTL is poor value based on its Price-To-Earnings Ratio (70.2x) compared to the UK Medical Equipment industry average (26.9x).

PE vs Market: TSTL is poor value based on its Price-To-Earnings Ratio (70.2x) compared to the UK market (15.3x).


Price to Earnings Growth Ratio

PEG Ratio: TSTL is poor value based on its PEG Ratio (1.7x)


Price to Book Ratio

PB vs Industry: TSTL is overvalued based on its Price-To-Book Ratio (5.8x) compared to the GB Medical Equipment industry average (2.8x).


Future Growth

How is Tristel forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

4/6

Future Growth Score 4/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


41.4%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TSTL's forecast earnings growth (41.4% per year) is above the savings rate (0.9%).

Earnings vs Market: TSTL's earnings (41.4% per year) are forecast to grow faster than the UK market (11.3% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: TSTL's revenue (10.6% per year) is forecast to grow faster than the UK market (4.1% per year).

High Growth Revenue: TSTL's revenue (10.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: TSTL's Return on Equity is forecast to be low in 3 years time (11.6%).


Past Performance

How has Tristel performed over the past 5 years?

Past Performance Score

1/6

Past Performance Score 1/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


1.0%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: TSTL has a large one-off loss of £874.0K impacting its December 31 2021 financial results.

Growing Profit Margin: TSTL's current net profit margins (7.6%) are lower than last year (14.4%).


Past Earnings Growth Analysis

Earnings Trend: TSTL's earnings have grown by 1% per year over the past 5 years.

Accelerating Growth: TSTL's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: TSTL had negative earnings growth (-50.1%) over the past year, making it difficult to compare to the Medical Equipment industry average (22.3%).


Return on Equity

High ROE: TSTL's Return on Equity (8.2%) is considered low.


Financial Health

How is Tristel's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: TSTL's short term assets (£17.4M) exceed its short term liabilities (£3.1M).

Long Term Liabilities: TSTL's short term assets (£17.4M) exceed its long term liabilities (£6.0M).


Debt to Equity History and Analysis

Debt Level: TSTL is debt free.

Reducing Debt: TSTL has not had any debt for past 5 years.

Debt Coverage: TSTL has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: TSTL has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Tristel current dividend yield, its reliability and sustainability?

Dividend Score

3/6

Dividend Score 3/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


1.93%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: TSTL's dividend (1.93%) is higher than the bottom 25% of dividend payers in the UK market (1.8%).

High Dividend: TSTL's dividend (1.93%) is low compared to the top 25% of dividend payers in the UK market (4.82%).


Stability and Growth of Payments

Stable Dividend: TSTL's dividend payments have been volatile in the past 10 years.

Growing Dividend: TSTL's dividend payments have increased over the past 10 years.


Earnings Payout to Shareholders

Earnings Coverage: With its high payout ratio (134.6%), TSTL's dividend payments are not well covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its reasonable cash payout ratio (68.3%), TSTL's dividend payments are covered by cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.4yrs

Average board tenure


CEO

Paul Swinney (62 yo)

29.33yrs

Tenure

UK£2,261,000

Compensation

Mr. Paul C. Swinney serves as the Chief Executive Officer of Tristel Plc. since 1993 and serves as its Director. Mr. Swinney started his career with Brown, Shipley & Co in 1980.He worked for the European...


CEO Compensation Analysis

Compensation vs Market: Paul's total compensation ($USD2.84M) is above average for companies of similar size in the UK market ($USD679.19K).

Compensation vs Earnings: Paul's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


Board Members

Experienced Board: TSTL's board of directors are considered experienced (3.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: TSTL insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Tristel plc's employee growth, exchange listings and data sources


Key Information

  • Name: Tristel plc
  • Ticker: TSTL
  • Exchange: AIM
  • Founded: 1993
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Implied Market Cap: UK£160.565m
  • Shares outstanding: 47.22m
  • Website: https://www.tristel.com

Number of Employees


Location

  • Tristel plc
  • Lynx Business Park
  • Unit 1B
  • Newmarket
  • Suffolk
  • CB8 7NY
  • United Kingdom

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/25 00:00
End of Day Share Price2022/05/25 00:00
Earnings2021/12/31
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.